Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 364

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice

Open access
Hermanowski-Vosatka, Anne, Balkovec, James M., Cheng, Kang, Chen, Howard Y., Hernandez, Melba, Koo, Gloria C., Le Grand, Cheryl B., Li, Zhihua, Metzger, Joseph M., Mundt, Steven S., Noonan, Heather, Nunes, Christian N., Olson, Steven H., Pikounis, Bill, Ren, Ning, Robertson, Nancy, Schaeffer, James M., Shah, Kashmira, Springer, Martin S., Strack, Alison M., Strowski, Matthias, Wu, Kenneth, Wu, TsueiJu, Xiao, Jianying, Zhang, Bei B., Wright, Samuel D., Thieringer, Rolf·2005·The Journal of Experimental Medicine

Abstract

The enzyme 11β–hydroxysteroid dehydrogenase (HSD) type 1 converts inactive cortisone into active cortisol in cells, thereby raising the effective glucocorticoid (GC) tone above serum levels. We report that pharmacologic inhibition of 11β-HSD1 has a therapeutic effect in mouse models of metabolic syndrome. Administration of a selective, potent 11β-HSD1 inhibitor lowered body weight, insulin, fasting glucose, triglycerides, and cholesterol in diet-induced obese mice and lowered fasting glucose, insulin, glucagon, triglycerides, and free fatty acids, as well as improved glucose tolerance, in a mouse model of type 2 diabetes. Most importantly, inhibition of 11β-HSD1 slowed plaque progression in a murine model of atherosclerosis, the key clinical sequela of metabolic syndrome. Mice with a targeted deletion of apolipoprotein E exhibited 84% less accumulation of aortic total cholesterol, as well as lower serum cholesterol and triglycerides, when treated with an 11β-HSD1 inhibitor. These data provide the first evidence that pharmacologic inhibition of intracellular GC activation can effectively treat atherosclerosis, the key clinical consequence of metabolic syndrome, in addition to its salutary effect on multiple aspects of the metabolic syndrome itself.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20050119

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 364

Metadata

Authors
Hermanowski-Vosatka, A., Balkovec, J. M., Cheng, K., Chen, H. Y., Hernandez, M., Koo, G. C., Le Grand, C. B., Li, Z., Metzger, J. M., Mundt, S. S., Noonan, H., Nunes, C. N., Olson, S. H., Pikounis, B., Ren, N., Robertson, N., Schaeffer, J. M., Shah, K., Springer, M. S., Strack, A. M., Strowski, M., Wu, K., Wu, T., Xiao, J., Zhang, B. B., Wright, S. D., & Thieringer, R.
Venue
The Journal of Experimental Medicine
Published
2005-08-15
Volume
202
Issue
4
Pages
517-527
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2100159933
Cited by
364
References
13
FWCI
24.65
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. https://app.cochat.ai/papers/10.1084/jem.20050119
The paper
Hermanowski-Vosatka, A., Balkovec, J. M., Cheng, K., Chen, H. Y., Hernandez, M., Koo, G. C., Le Grand, C. B., Li, Z., Metzger, J. M., Mundt, S. S., Noonan, H., Nunes, C. N., Olson, S. H., Pikounis, B., Ren, N., Robertson, N., Schaeffer, J. M., Shah, K., Springer, M. S., . . . Thieringer, R. (2005). 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. The Journal of Experimental Medicine. https://doi.org/10.1084/jem.20050119

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.